CHEN JIN-LONG 4
4 · NGM BIOPHARMACEUTICALS INC · Filed Dec 7, 2021
Insider Transaction Report
Form 4
CHEN JIN-LONG
DirectorChief Scientific Officer
Transactions
- Sale
Common Stock
2021-12-06$18.21/sh−15,000$273,150→ 854,449 total - Sale
Common Stock
2021-12-07$18.60/sh−15,000$279,000→ 908,893 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-12-06−69,444→ 85,082 totalExercise: $1.44Exp: 2023-01-23→ Common Stock (69,444 underlying) - Exercise/Conversion
Common Stock
2021-12-06$1.44/sh+69,444$99,999→ 923,893 total
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2021.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.79 to $18.49. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $18.10 to $18.99. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Fully vested.